Key result
Novel risk grading system identifies patients with a ~56% 30-day risk of symptomatic BKPyV replication.
Why the study?
BK polyomavirus replication independently predicts chronic kidney disease and poor survival and is associated with increased morbidity and mortality in allogeneic stem cell transplant recipients, but a user-friendly risk grading system was needed to identify patients at risk.
Can a risk grading system predict symptomatic BKPyV replication in allogeneic stem cell transplant recipients?
Cohort (n=3,955)
Can a risk grading system predict symptomatic BKPyV replication in allogeneic stem cell transplant recipients?
A 3-variable risk grading system can stratify allogeneic stem cell transplant recipients by their risk of developing symptomatic BKPyV replication.
May aid BKPyV risk stratification after allogeneic transplant; leaves open prospective validation before guiding care.
BACKGROUND: BK polymavirus (BKPyV), a member of the family Polyomaviridae, is associated with increased morbidity and mortality in allogeneic stem cell transplant recipients. METHODS: In our previous retrospective study of 2477 stem cell transplant patients, BKPyV replication independently predicted chronic kidney disease and poor survival. In this study, using the same cohort, we derived and validated a risk grading system to identify patients at risk of BKPyV replication after transplantation in a user-friendly modality. We used 3 baseline variables (conditioning regimen, HLA match status, and underlying cancer diagnosis) that significantly predicted BKPyV replication in our initial study in a subdistribution hazard model with death as a competing risk. We also developed a nomogram of the hazard model as a visual aid. The AUC of the ROC of the risk-score-only model was 0.65. We further stratified the patients on the basis of risk score into low-, moderate-, and high-risk groups. RESULTS: The total risk score was significantly associated with BKPyV replication (P < .0001). At 30 days after transplantation, the low-risk (score ≤ 0) patients had a 9% chance of developing symptomatic BKPyV replication, while the high-risk (score ≥ 8) of the population had 56% of developing BKPyV replication. We validated the risk score using a separate cohort of 1478 patients. The AUC of the ROC of the risk-score-only model was 0.59. Both the total risk score and 3-level risk variable were significantly associated with BKPyV replication in this cohort (P < .0001). CONCLUSIONS: This grading system for the risk of symptomatic BKPyV replication may help in early monitoring and intervention to prevent BKPyV-associated morbidity, mortality, and kidney function decline.
No takes yet. Share an insight, caveat, or question.
Abudayyeh et al. (2020) conducted a cohort in Allogeneic stem cell transplant (n=3,955). High risk score (≥ 8) vs. Low risk score (≤ 0) was evaluated on Symptomatic BKPyV replication (p=<.0001). A novel risk grading system identified that high-risk patients had a 56% chance of developing symptomatic BKPyV replication at 30 days compared to 9% in low-risk patients (P<.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: